Welcome to ACCP Learning Management System

Access all your CE needs here!

Upcoming live webinars are listed below

To view the entire CE catalog, click on Catalog in the box to the right

To view CE products that you have already purchased, click on Dashboard in the box to the right. You need to be logged in to view your Dashboard

If you need assistance, email CE@ACCP1.org or phone 571-291-3493 ext 2

Upcoming Live Webinars

  • Includes a Live Web Event on 03/20/2024 at 2:15 PM (EDT)

    Edoxaban 60 mg is approved for stroke prevention in patients with atrial fibrillation (AF) not fulfilling any dose-reduction criteria. As edoxaban is partially renally cleared (≈50%), it was postulated that edoxaban exposure may be lower in patients with high creatinine clearance (CrCL >100 mL/min); thus, efficacy could hypothetically be lower in this subpopulation. In this webinar, the author will discuss a prospective, randomized, double-blinded study comparing the pharmacokinetics, pharmacodynamics, efficacy and safety outcomes of edoxaban 60 mg once daily versus edoxaban 75 mg once daily in patients with CrCL exceeding 100 mL/min. The presentation will also illustrate the utility of population PK modeling to account for variability and estimate steady-state PK values based on the sparse PK concentrations collected in the study.

Featured Learning